Page 35 - Evercore Group News Today

Phathom Pharmaceuticals Announces Proposed Public Offering of 2,250,000 Shares of Common Stock Phathom Pharmaceuticals Announces Proposed Public Offering of 2,250,000 Shares of Common Stock FLORHAM PARK, N.J., Dec. 15, 2020 — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it intends to offer and sell, subject to market and other conditio...

NANOBIOTIX Announces Closing of Global Offering and Full Exercise of Underwriters Option to Purchase Additional ADSs, Bringing Gross Proceeds of Global Offering to $113.3 Million Nanobiotixs ADSs began trading on the Nasdaq Global Select Market on December 11, 2020. Announced full exercise of underwriters option to purchase additional American Depositary Shares (ADSs), with closing expected to take place on December 18, 2020. Will add approximately $14.8 million in additional gross proceeds for...

Mirum Pharmaceuticals Announces Pricing of Public Offering of Common Stock Mirum Pharmaceuticals Announces Pricing of Public Offering of Common Stock Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced the pricing of its previously announced underwritten public offering of 3,750,000 shares of its common stock at a price to the public...

TG Therapeutics Announces Proposed Public Offering of Common Stock TG Therapeutics Announces Proposed Public Offering of Common Stock NEW YORK, Dec. 14, 2020 — TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases (“TG Therapeutics”), today announced that it has commenced an underwritten public offering of $200,000,000 of its common stock. The offering is subject to market and other conditions, an...

Message : Required fields EMERYVILLE, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced today the closing of its initial public offering of 9,660,000 shares of its common stock, including 1,260,000 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a price of $23.00 per share. The aggregat...

NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN : FR0011341205 – the ‘‘ Company’’), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the pricing of its initial public offering on the Nasdaq Global Select Market by way of a capital increase of 7,300,000 new ordinary shares (the “ New Shares”), consisting of a public offering of 5,445,000 ordinary shares in the form of American Depositary Shares (“ ADSs”), each represen...

IPO Alert: Nanobiotix (NBTX) PARIS (dpa-AFX) - Paris, France-based Nanobiotix, which is currently listed on the Euronext Paris stock exchange, is scheduled to list its American Depositary Shares (ADSs) on the Nasdaq Global Market under the symbol NBTX today (December 11). Nanobiotix is a clinical-stage biotechnology company developing first-in-class product candidates that use proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company has of...